Why are tech companies growing medicine in zero gravity?
Space-made medicines don’t lose their shape on Earth. See how permanent microgravity crystal stability locks in structure to boost medicine absorption.
Key Takeaways
What: Varda Space Industries manufactures pharmaceuticals in low-Earth orbit.
Why: Zero gravity forms uniform crystals that stay permanently stable after Earth reentry, improving drug absorption.
How: Unmanned space capsules process formulations in orbit and return the crystallized medicines safely to Earth.
Microgravity Pharmaceutical Manufacturing and Space Tech Commercialization
Permanent Microgravity Crystallization: The Terrestrial Absorption Advantage
When chemical ingredients travel into low-Earth orbit, their physical behavior shifts in response to microgravity. Life sciences startup Varda Space Industries utilizes this environment to formulate new pharmaceuticals. In zero gravity, materials form crystals that maintain an exceptional level of uniform size and structure. This precise structural arrangement cannot be reproduced anywhere on Earth.
Common industry assumptions suggest that crystal alignment formed in space would degrade upon returning to Earth’s atmosphere. However, materials processed in orbit remain permanently locked in their crystallized state after returning to Earth. This permanent physical stability allows the resulting medicines to deliver higher absorption rates and improved therapeutic effectiveness for patients.
Flight Operations and Mission Cadence (2027–2029)
Translating orbital chemistry into consistent manufacturing relies on dedicated spacecraft hardware. Varda has completed launch and return missions for six unmanned space capsules. To expand capacity, the company sent two new spacecrafts, the W8 and W9, into orbit on a single rocket launch.
Operational plans focus on building a routine manufacturing cadence. Between 2027 and 2029, Varda plans to conduct 28 additional missions into low-Earth orbit.
Balance Sheet Metrics and Space Sector Capitalization
Scaling orbital manufacturing requires substantial capital allocation. Varda recently closed a $250M funding round, raising its total funding to $598M.
This capital influx aligns with broader momentum across commercial space tech startups, which have secured more than $20.3B in funding this year alone. Enterprise founders and investors are targeting commercial opportunities within low-Earth orbit.
The Broader $1.8T Space Economy Landscape
Projections from the World Economic Forum estimate that the global space economy could reach $1.8T by 2035. While life sciences manufacturing represents an expanding branch, defense and environmental monitoring remain major commercial sectors.
Within defense, low-Earth orbit satellites deliver real-time surveillance and sensing data for military operations. European company Iceye operates a constellation of over 75 satellites, maintaining major contracts with the United States, Germany, Portugal, and Finland. Iceye expects to exceed €500M in revenue this year, doubling its previous annual revenue performance.
Simultaneously, environmental applications continue to draw substantial investment. Startup Muon Space recently secured a $250M funding round and holds a $1.5B valuation. The company operates satellites designed to monitor wildfires, weather conditions, and agricultural land.